⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent acute myeloid leukemia

Every month we try and update this database with for recurrent acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantNCT05799079
Recurrent Acute...
Venetoclax
Decitabine
Cedazuridine
Bone Marrow Asp...
Biospecimen Col...
18 Years - Vanderbilt-Ingram Cancer Center
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaNCT05396859
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Entrectinib
Laboratory Biom...
18 Years - OHSU Knight Cancer Institute
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell TransplantNCT01640301
Recurrent Adult...
Recurrent Child...
Secondary Acute...
Therapy-Related...
Donor
Hematopoietic C...
HLA-A*0201 Posi...
Recurrent Acute...
Aldesleukin
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
WT1-Sensitized ...
- Fred Hutchinson Cancer Center
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaNCT03009240
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Therapy-Related...
Untreated Adult...
Decitabine
Laboratory Biom...
Pevonedistat
Pharmacological...
18 Years - City of Hope Medical Center
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryNCT03969446
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Decitabine
Pembrolizumab
Venetoclax
18 Years - City of Hope Medical Center
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaNCT03629171
Recurrent Acute...
Refractory Acut...
Liposome-encaps...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03745352
Recurrent Acute...
Refractory Acut...
Azacitidine
Pevonedistat
18 Years - National Cancer Institute (NCI)
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationNCT03602898
Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 YearsFred Hutchinson Cancer Center
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseNCT04146038
Acute Myeloid L...
Chronic Myelomo...
Myeloblasts 10 ...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Azacitidine
Decitabine
Salsalate
Venetoclax
18 Years - Rutgers, The State University of New Jersey
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT01892371
FLT3 Gene Mutat...
FLT3 Internal T...
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Chro...
Refractory Myel...
Azacitidine
Cytarabine
Quizartinib
18 Years - M.D. Anderson Cancer Center
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeNCT04487106
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Chro...
Refractory Myel...
Azacitidine
Trametinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNCT01822509
Allogeneic Hema...
Myeloproliferat...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Chron...
Recurrent Hemat...
Recurrent Hodgk...
Recurrent Myelo...
Recurrent Non-H...
Recurrent Plasm...
Ipilimumab
Laboratory Biom...
Nivolumab
18 Years - National Cancer Institute (NCI)
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationNCT04203316
Recurrent Acute...
Refractory Acut...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Enasidenib
Enasidenib Mesy...
24 Months - 21 YearsChildren's Oncology Group
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaNCT02953561
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Avelumab
Azacitidine
Laboratory Biom...
18 Years - M.D. Anderson Cancer Center
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT05010122
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Gilteritinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT03813147
Acute Myeloid L...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Azacitidine
Cytarabine
Fludarabine Pho...
Methotrexate
Pevonedistat
Therapeutic Hyd...
1 Month - 21 YearsNational Cancer Institute (NCI)
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT04047641
Acute Myeloid L...
Blasts 20 Perce...
High Risk Myelo...
Recurrent Acute...
Recurrent Acute...
Recurrent High ...
Refractory Acut...
Refractory High...
Cladribine
Cytarabine
Idarubicin
Quizartinib
18 Years - M.D. Anderson Cancer Center
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaNCT06399640
Relapsed Myelod...
Refractory Myel...
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Eltanexor
Venetoclax
Bone Marrow Asp...
Biospecimen Col...
18 Years - Vanderbilt-Ingram Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT04493164
Acute Myeloid L...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Ivosidenib
Liposome-encaps...
18 Years - M.D. Anderson Cancer Center
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid LeukemiaNCT04158739
Recurrent Acute...
Refractory Acut...
Cytarabine
Flotetuzumab
- 20 YearsChildren's Oncology Group
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeNCT03670966
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Recurrent Mixed...
Refractory Mixe...
Hematopoietic a...
Astatine At 211...
Cyclophosphamid...
Total-Body Irra...
Peripheral Bloo...
Bone Marrow Tra...
Mycophenolate M...
Recombinant Gra...
Fludarabine Pho...
Tacrolimus
Bone Marrow Asp...
Biospecimen Col...
18 Years - 75 YearsFred Hutchinson Cancer Center
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaNCT03983824
Recurrent Acute...
Refractory Acut...
Cytarabine
Etoposide Phosp...
Mitoxantrone Hy...
Peposertib
18 Years - National Cancer Institute (NCI)
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaNCT02890329
Previously Trea...
Recurrent Acute...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Secondary Acute...
Secondary Myelo...
Decitabine
Ipilimumab
18 Years - National Cancer Institute (NCI)
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT03067571
High Risk Myelo...
Recurrent Acute...
Refractory Acut...
Daratumumab
18 Years - M.D. Anderson Cancer Center
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxNCT05222984
Recurrent Acute...
Refractory Acut...
Decitabine
Navitoclax
Venetoclax
16 Years - City of Hope Medical Center
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSNCT05456269
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Higher Risk Mye...
Chronic Myelomo...
Bisantrene Dihy...
Bisantrene Dihy...
Cytarabine Hydr...
Decitabine and ...
18 Years - Race Oncology Ltd
NK Cells in Cord Blood TransplantationNCT01619761
Accelerated Pha...
Acute Biphenoty...
Acute Lymphobla...
Acute Myeloid L...
Chronic Phase C...
DS Stage II Pla...
DS Stage III Pl...
High Grade B-Ce...
ISS Stage II Pl...
ISS Stage III P...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Small...
Refractory Acut...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
Secondary Acute...
Therapy-Related...
Therapy-Related...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Lenalidomide
Melphalan
Mycophenolate M...
Natural Killer ...
Rituximab
Tacrolimus
Total-Body Irra...
Umbilical Cord ...
- 75 YearsM.D. Anderson Cancer Center
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaNCT03557970
Recurrent Acute...
Refractory Acut...
Edicotinib
Pharmacokinetic...
18 Years - OHSU Knight Cancer Institute
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaNCT03214562
High Risk Myelo...
Recurrent Acute...
Refractory Acut...
Cytarabine
Filgrastim
Fludarabine
Idarubicin
Pegfilgrastim
Venetoclax
18 Years - M.D. Anderson Cancer Center
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLNCT04493099
Recurrent Acute...
Refractory Acut...
Alvocidib Hydro...
Decitabine
Venetoclax
18 Years - M.D. Anderson Cancer Center
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatNCT05320380
Recurrent Acute...
Recurrent B Acu...
Recurrent Mixed...
Recurrent T Acu...
Refractory Acut...
Refractory B Ac...
Refractory Mixe...
Refractory T Ac...
Anti-CD123 ADC ...
Bone Marrow Asp...
Cytarabine
Fludarabine Pho...
Hydrocortisone ...
Liposome-encaps...
Methotrexate
Prednisolone
12 Months - 22 YearsChildren's Oncology Group
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaNCT03634228
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Cytarabine
Milademetan Tos...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Anti-Leukemia Immune Responses After Irradiation of Extramedullary TumorsNCT05035706
Acute Myeloid L...
Myeloid Leukemi...
Recurrent Acute...
Biopsy
Biospecimen Col...
Electronic Heal...
Photography
18 Years - M.D. Anderson Cancer Center
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaNCT03009240
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Therapy-Related...
Untreated Adult...
Decitabine
Laboratory Biom...
Pevonedistat
Pharmacological...
18 Years - City of Hope Medical Center
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseNCT04146038
Acute Myeloid L...
Chronic Myelomo...
Myeloblasts 10 ...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Azacitidine
Decitabine
Salsalate
Venetoclax
18 Years - Rutgers, The State University of New Jersey
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDNCT02220985
Accelerated Pha...
Acute Biphenoty...
Acute Leukemia ...
Acute Undiffere...
Allogeneic Hema...
Blast Phase Chr...
Blastic Plasmac...
Childhood Acute...
Childhood Acute...
Donor
Lymphoblastic L...
Myelodysplastic...
Myelodysplastic...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Refractory Acut...
Refractory Acut...
Acute Lymphobla...
Acute Myeloid L...
Allogeneic Hema...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Methotrexate
Mycophenolate M...
Peripheral Bloo...
Peripheral Bloo...
Tacrolimus
Thiotepa
Total-Body Irra...
- 60 YearsFred Hutchinson Cancer Center
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantNCT02684162
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Donor Lymphocyt...
Guadecitabine
Laboratory Biom...
18 Years - 75 YearsM.D. Anderson Cancer Center
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03874052
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Ruxolitinib
Venetoclax
18 Years - OHSU Knight Cancer Institute
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaNCT03214562
High Risk Myelo...
Recurrent Acute...
Refractory Acut...
Cytarabine
Filgrastim
Fludarabine
Idarubicin
Pegfilgrastim
Venetoclax
18 Years - M.D. Anderson Cancer Center
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaNCT04207190
Recurrent Acute...
Refractory Acut...
Gemtuzumab Ozog...
Quality-of-Life...
Questionnaire A...
Talazoparib
Talazoparib Tos...
18 Years - Roswell Park Cancer Institute
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaNCT04375631
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Chro...
Refractory Mixe...
Refractory Myel...
Refractory Acut...
Refractory Acut...
Cladribine
Cyclophosphamid...
Cyclosporine
Cytarabine
Filgrastim
Hematopoietic C...
Mitoxantrone
Mycophenolate M...
Mycophenolate S...
Total-Body Irra...
Idarubicin
Fludarabine
Cytarabine
Multigated Acqu...
Echocardiograph...
X-Ray Imaging
Bone Marrow Bio...
Bone Marrow Asp...
18 Years - Fred Hutchinson Cancer Center
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaNCT01904136
Accelerated Pha...
Acute Myeloid L...
Acute Myeloid L...
Blast Phase Chr...
de Novo Myelody...
Myelodysplastic...
Recurrent Acute...
Recurrent Chron...
Therapy-Related...
Allogeneic Hema...
Bone Marrow Tra...
Cyclophosphamid...
Fludarabine
Laboratory Biom...
Melphalan
Mycophenolate M...
Natural Killer ...
Peripheral Bloo...
Tacrolimus
Total-Body Irra...
2 Years - 65 YearsM.D. Anderson Cancer Center
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeNCT03661307
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Decitabine
Quizartinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationNCT03683433
Acute Bilineal ...
Acute Biphenoty...
Chronic Myelomo...
IDH2 Gene Mutat...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Azacitidine
Enasidenib Mesy...
18 Years - M.D. Anderson Cancer Center
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyNCT03063944
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
STAT Inhibitor ...
Decitabine
Venetoclax
Laboratory Biom...
18 Years - Thomas Jefferson University
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationNCT04203316
Recurrent Acute...
Refractory Acut...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Enasidenib
Enasidenib Mesy...
24 Months - 21 YearsChildren's Oncology Group
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationNCT03683433
Acute Bilineal ...
Acute Biphenoty...
Chronic Myelomo...
IDH2 Gene Mutat...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Azacitidine
Enasidenib Mesy...
18 Years - M.D. Anderson Cancer Center
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaNCT04188405
Accelerated Pha...
Acute Myeloid L...
Blast Phase Chr...
Recurrent Acute...
Recurrent Chron...
Refractory Acut...
Refractory Chro...
Decitabine
Ponatinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaNCT05396859
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Entrectinib
Laboratory Biom...
18 Years - OHSU Knight Cancer Institute
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaNCT03132454
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Decitabine
Dexamethasone
Palbociclib
Sorafenib
15 Years - M.D. Anderson Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT04493164
Acute Myeloid L...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Ivosidenib
Liposome-encaps...
18 Years - M.D. Anderson Cancer Center
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaNCT02397720
Acute Bilineal ...
Acute Biphenoty...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Therapy-Related...
Azacitidine
Ipilimumab
Laboratory Biom...
Nivolumab
18 Years - M.D. Anderson Cancer Center
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaNCT04774393
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Enasidenib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryNCT03969446
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Decitabine
Pembrolizumab
Venetoclax
18 Years - City of Hope Medical Center
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantNCT02684162
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Donor Lymphocyt...
Guadecitabine
Laboratory Biom...
18 Years - 75 YearsM.D. Anderson Cancer Center
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaNCT03132454
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Decitabine
Dexamethasone
Palbociclib
Sorafenib
15 Years - M.D. Anderson Cancer Center
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeNCT04128748
Acute Myeloid L...
Blasts More Tha...
High Risk Myelo...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Liposome-encaps...
Quizartinib
18 Years - M.D. Anderson Cancer Center
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSNCT05456269
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Higher Risk Mye...
Chronic Myelomo...
Bisantrene Dihy...
Bisantrene Dihy...
Cytarabine Hydr...
Decitabine and ...
18 Years - Race Oncology Ltd
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaNCT04250051
Recurrent Acute...
Recurrent Myelo...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Cytarabine
Filgrastim
Fludarabine
Fludarabine Pho...
Ivosidenib
18 Years - Northwestern University
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell TransplantNCT01640301
Recurrent Adult...
Recurrent Child...
Secondary Acute...
Therapy-Related...
Donor
Hematopoietic C...
HLA-A*0201 Posi...
Recurrent Acute...
Aldesleukin
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
WT1-Sensitized ...
- Fred Hutchinson Cancer Center
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationNCT03953898
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Biospecimen Col...
Bone Marrow Asp...
Olaparib
18 Years - National Cancer Institute (NCI)
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureNCT04905810
Acute Myeloid L...
Recurrent Acute...
Azacitidine
Decitabine
Venetoclax
18 Years - University of California, Davis
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaNCT06399640
Relapsed Myelod...
Refractory Myel...
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Eltanexor
Venetoclax
Bone Marrow Asp...
Biospecimen Col...
18 Years - Vanderbilt-Ingram Cancer Center
Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaNCT05627232
Recurrent Acute...
Refractory Acut...
Tazemetostat
Liposome-encaps...
Bone Marrow Asp...
Biospecimen Col...
Palbociclib
18 Years - Thomas Jefferson University
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT03772925
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Belinostat
Pevonedistat
18 Years - National Cancer Institute (NCI)
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNCT05010122
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Gilteritinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaNCT04752163
Hematopoietic a...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Acut...
Refractory Chro...
Refractory Myel...
DS-1594b
Azacitidine
Cyclophosphamid...
Cytarabine
Dexamethasone
Filgrastim
Leucovorin
Mesna
Methotrexate
Posaconazole
Prednisone
Rituximab
Venetoclax
Vincristine
Voriconazole
18 Years - M.D. Anderson Cancer Center
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute LeukemiaNCT03128034
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Recurrent Acute...
Recurrent Mixed...
Refractory Acut...
Refractory Mixe...
Mixed Phenotype...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Pretargeted Rad...
Total-Body Irra...
18 Years - 75 YearsFred Hutchinson Cancer Center
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatNCT05320380
Recurrent Acute...
Recurrent B Acu...
Recurrent Mixed...
Recurrent T Acu...
Refractory Acut...
Refractory B Ac...
Refractory Mixe...
Refractory T Ac...
Anti-CD123 ADC ...
Bone Marrow Asp...
Cytarabine
Fludarabine Pho...
Hydrocortisone ...
Liposome-encaps...
Methotrexate
Prednisolone
12 Months - 22 YearsChildren's Oncology Group
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeNCT03672539
Acute Myeloid L...
Chronic Myelomo...
High Risk Myelo...
Myelodysplastic...
Recurrent Acute...
Refractory Acut...
Gemtuzumab Ozog...
Liposome-encaps...
Quality-of-Life...
18 Years - M.D. Anderson Cancer Center
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantNCT03247088
Recurrent Acute...
Refractory Acut...
Allogeneic Hema...
Busulfan
Cyclophosphamid...
Filgrastim
Fludarabine
Mycophenolate M...
Sorafenib
Tacrolimus
18 Years - 70 YearsM.D. Anderson Cancer Center
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1NCT04874194
Hematopoietic a...
Recurrent Acute...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Acut...
Refractory Myel...
Omacetaxine Mep...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1NCT04874194
Hematopoietic a...
Recurrent Acute...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Acut...
Refractory Myel...
Omacetaxine Mep...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaNCT02890329
Previously Trea...
Recurrent Acute...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Secondary Acute...
Secondary Myelo...
Decitabine
Ipilimumab
18 Years - National Cancer Institute (NCI)
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeNCT03404193
Acute Myeloid L...
Acute Myeloid L...
Blastic Plasmac...
Chronic Myelomo...
Mixed Phenotype...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Recurrent Blast...
Recurrent Chron...
Recurrent Mixed...
Refractory Acut...
Refractory Blas...
Refractory Chro...
Refractory Mixe...
Decitabine
Laboratory Biom...
Venetoclax
18 Years - M.D. Anderson Cancer Center
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyNCT03063944
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
STAT Inhibitor ...
Decitabine
Venetoclax
Laboratory Biom...
18 Years - Thomas Jefferson University
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryNCT03969446
Acute Myeloid L...
Myelodysplastic...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Decitabine
Pembrolizumab
Venetoclax
18 Years - City of Hope Medical Center
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaNCT04975919
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Decitabine and ...
Venetoclax
18 Years - M.D. Anderson Cancer Center
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesNCT03471260
Acute Myeloid L...
Hematopoietic a...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Azacitidine
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaNCT04435691
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Azacitidine
Magrolimab
Venetoclax
18 Years - M.D. Anderson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: